The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Bispecific antibodies as a standard of care for R/R LBCL: a multicenter real-world study
Julio Chavez, MD, Moffitt Cancer Center, Tampa, FL, comments on the preliminary results of a multicenter real-world study evaluating the use of bispecific antibodies as a standard of care for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Chavez highlights that the study showed similar responses to those reported in clinical trials but also identified a key finding: patients who are CAR-T refractory tend to have poor responses to bispecifics, suggesting a shared mechanism of resistance related to tumor microenvironment and inflammation. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
